I agree with your comment of '- has run the company to insolvency once already and shortly to issue 750 million shares to fund his truths - but not one .35 of a penny of his own money - why dont you invest your money in the sareum pipeline tim -'
However I wouldn't be too hasty with the strong sell IMO
The same but different - phew - no sign of big pharma here - because no one believes him -
- has run the company to insolvency once already and shortly to issue 750 million shares to fund his truths - but not one .35 of a penny of his own money - why dont you invest your money in the sareum pipeline tim -
this is his proactive interview enticing investors into his near bust company and then dilutes them over and over again - “We know the deal sizes go up exponentially as you go down the track. But it is important for us to do a deal sooner rather than later. but you didn't did you Tim
“We have yet to demonstrate through our own research that we can produce something someone is willing to pay for. The first deals we will do early. The next we will look to push into the clinic.” another truth - you didn't Tim did you
“We have been saying we will do a deal in the next six months for quite a while now. Maybe this time it will be true.”
another truth enticing investors to fund his lifestyle “Our forte is being very nimble and to follow up with this best in class rather than first in class model,” Mitchell said.
“This is how we beat the big companies at their own game. In fact I would go as far as to say the big companies have shown they are not very good at research yet they spend a lot of money on it.”
But you are not spending your money on Sareum are you Tim -
Tim like so many other shares - BHR Sefton Range is a director with no track record in telling the whole story Where is the share buying by you in the last ten years Tim - you are beating big pharma aren't you Tim
Those two trades were mine, 1 is a sell , the other one is a buy back into my ISA (although both showing as sells) thought it would be good idea at current the low price so that my ISA subscription limit isn't impacted too much...
Not sure if it a missed opportunity. SAR 20347 inhibits different things (interleukin 22/23 rather than 17) and there isn't anything in clinical trials or on the market, as far as I can see, that targets the same as TYK2
Maybe the approval of a similar yet different drug might spur on other big pharmas to license in to TYK2.
Dr Tim - commander in chief - where are you - from 1.65p at AGM when the overpaid chairman read out no deal (surprise ) to .35p and you are not buying any shares - look at all that shareholder value - and the flexibility wonga merchants have given you - just how flexible is it now
you have led the company to almost insolvency a second time - and you know full well that you are economical with the truth - just how does the "structured finance deal" according to a know all on this board work out - because had you been a CEO of any merit you would see that wonga merchants dilute dilute dilute
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.